← Back to Search

CAR T-cell Therapy

CAR T-Cell Therapy for Lung Cancer

Phase < 1
Recruiting
Led By Jared Weiss
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject must be platinum-refractory and either currently receiving or has previously received a PD1/PDL1 inhibitor
Be older than 18 years old
Must not have
Subject does not have adequate organ function
Subject did not receive platinum-based chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Summary

This trial is testing a combination of antibodies and T cells to treat lung cancer. It will look at how much of the treatment is safe and what dosage is the most effective.

Who is the study for?
This trial is for adults with advanced lung cancer that's resistant to platinum chemotherapy and has been treated with PD-1/PD-L1 inhibitors. Participants must be in good enough health, have a life expectancy of at least 12 weeks, and women able to have children need a negative pregnancy test before cell collection.Check my eligibility
What is being tested?
The study tests autologous T lymphocyte chimeric antigen receptor cells targeting GD2 (iC9.GD2.CAR.IL-15 T cells). It aims to find the safe dosage levels of these modified immune cells designed to fight lung cancer more effectively than antibodies or T cells alone.See study design
What are the potential side effects?
Potential side effects may include reactions related to the immune system such as fever, fatigue, and flu-like symptoms; risk of infection; possible organ inflammation due to an overactive immune response; and infusion-related reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have cancer that did not respond to platinum-based treatment and have been treated with a PD1/PDL1 inhibitor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My organs are not functioning properly.
Select...
I have not had platinum-based chemotherapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cytokine Release Syndrome (CRS)
Neurotoxicity
Number of participants with adverse event
Secondary outcome measures
Disialoganglioside (GD2) Expression
Neoplasms
Duration of Benefit
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: iC9.GD2.CAR.IL-15 T TherapyExperimental Treatment1 Intervention
Experimental: Single Arm Subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy will receive iC9.GD2.CAR.IL-15 T cells were manufactured from their collected blood sample.

Find a Location

Who is running the clinical trial?

United States Department of DefenseFED
875 Previous Clinical Trials
329,962 Total Patients Enrolled
UNC Lineberger Comprehensive Cancer CenterLead Sponsor
354 Previous Clinical Trials
91,434 Total Patients Enrolled
Bellicum PharmaceuticalsIndustry Sponsor
27 Previous Clinical Trials
1,328 Total Patients Enrolled

Media Library

iC9.GD2.CAR.IL-15 T cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05620342 — Phase < 1
Non-Small Cell Lung Cancer Research Study Groups: iC9.GD2.CAR.IL-15 T Therapy
Non-Small Cell Lung Cancer Clinical Trial 2023: iC9.GD2.CAR.IL-15 T cells Highlights & Side Effects. Trial Name: NCT05620342 — Phase < 1
iC9.GD2.CAR.IL-15 T cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05620342 — Phase < 1
~8 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top